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Bovine papillomavirus type 1 (BPV-1) encodes two regulatory proteins, E1 and E2, that are essential for viral replication and
transcription. E1, an ATP-dependent helicase, binds to the viral ori and is essential for viral replication, while the viral
transcriptional activator, E2, plays cis-dominant roles in both viral replication and transcription. At low reporter concentra-
tions, E1 stimulates E2 enhancer function, while at high reporter concentrations, repression results. An analysis of cis
requirements revealed that neither replication nor specific E1-binding sites are required for the initiators’ effect on E2
transactivator function. Though no dependence on E1-binding sites was found, analysis of E1 DNA binding and ATPase
mutants revealed that both domains are required for E1 modulation of E2. Through the use of E2 fusion-gene constructs we
showed that a heterologous DNA-binding domain could be substituted for the E2 DNA-binding domain and this recombinant
protein remained responsive to E1. Furthermore, E1 could rescue activation domain mutants of E2 defective for transacti-
vation. These data suggest that E1 stimulation of E2 involves interactions between E1 and the E2 activation domain on DNA.
We speculate that E1 may allosterically interact with the E2 activation domain, perhaps stabilizing a particular structure,
which increases the enhancer function of E2. © 2000 Academic Press
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The bovine papillomavirus (BPV) transformation pro-
cess has been an interesting model for understanding
how transcription and replication occur in higher eu-
karyotes and how these aspects of DNA function may be
coordinately regulated. Latently, the viral genome repli-
cates as a stable nuclear plasmid in synchrony with the
host cell cycle, requiring host cell machinery for both its
replication and gene expression. The key events of the
BPV plasmid state are regulated by two virally encoded
proteins, the E1 initiator protein and the transcriptional
activator, E2. Replication of BPV, in vivo and in vitro,
requires the E1 protein. This protein recognizes the viral
origin as a monomer but in an ATP-dependent step E1
oligomerizes to form a functional helicase that binds the
origin of replication (ori) as a hexamer and interacts with
cellular DNA polymerase a-primase and the cyclin
–cdk2 complex (Cueille et al., 1998; Fouts et al., 1999;
edman and Stenlund, 1998; Stenlund, 1996). Replication
f BPV in vivo also requires the E2 protein (Ustav and
tenlund, 1991), while in vitro, E2 functions as a replica-
ion enhancer stimulating DNA replication and is only
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430bsolutely required for DNA replication at limiting con-
entrations of the E1 protein (Yang et al., 1991a).
The E2 transactivator has a modular structure contain-
ng an amino-terminal activation domain and a carboxy-
erminal DNA-binding and dimerization domain sepa-
ated by an unstructured “hinge” region (McBride et al.,
989). The E2 ORF encodes the full-length E2 transacti-
ator, as well as two amino-terminal truncations, E2C
nd E8E2, that lack the activation domain and act as
ranscriptional and replication repressors (Choe et al.,
989; Hubbert et al., 1988; Lambert and Howley, 1988;
im et al., 1998). E2 interacts directly with E1, and the two
roteins bind cooperatively to DNA (Mohr et al., 1990). It
s this cooperative binding that mainly explains E2’s
eplication enhancer activity, as the cooperativity is re-
uired for targeting the E1 monomers to the origin site
nder physiological conditions. Relative to the full-length
orms, the two repressor forms of E2 do not cooperatively
nteract with the E1 replication factor (Lim et al., 1998;
ohr et al., 1990). Mutational analysis of E2 also indi-
ates that the major surface of E2 that interacts with E1
s the amino-terminal activation domain (Benson and
owley, 1995; Ferguson and Botchan, 1996; Winokur and
cBride, 1996). There is now compelling evidence that
he E2 DNA-binding domain also interacts with E1, albeit
t the DNA site weakly, and that this interaction is im-
ortant for development of a preinitiation complex (Berg
nd Stenlund, 1997; Chen and Stenlund, 1998).
The role of the E2 transactivator as a specificity factor
or targeting E1 to the origin site has been firmly estab-
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431BPV E1 MODULATES E2 ENHANCER FUNCTIONlished (Mohr et al., 1990; Sedman and Stenlund, 1995,
1998; Sedman et al., 1997; Ustav and Stenlund, 1991;
ang et al., 1991a). In the presence of both E1 and E2
proteins, strong E2-binding sites can compensate for
mutations in the E1 origin-binding site as judged by
DNA-binding assays in vitro and in replication assays
both in vivo and in vitro (Sedman and Stenlund, 1996;
Spalholz et al., 1993). Reciprocally, it was demonstrated
hat E1 mutants crippled for DNA binding can be rescued
or binding in vitro by addition of E2 and, in some cases,
an be rescued for their ability to promote replication in
ivo (Thorner et al., 1993). The central role of E2 in
egulating viral DNA functions is further illustrated by the
act that the transactivator serves to tether the BPV ge-
ome to cellular chromosomes, providing a mechanism
or maintenance of BPV as a nuclear plasmid (Ilves et al.,
999; Lehman and Botchan, 1998; Skiadopoulos and
cBride, 1998). Second-site suppressor mutations of the
2 phosphorylation mutant defective in plasmid mainte-
ance were found in both E2 and E1, suggesting a
otential role for E1 in plasmid maintenance (Lehman
nd Botchan, 1998).
Several lines of evidence suggest a role for E1 in
odulating E2-dependent transactivation, including the
rganization of the BPV regulatory region, commonly
nown as the upstream regulatory region (URR). BPV E2
nd its two repressor forms, E2C and E8E2, bind to 17
ites within the viral genome, 12 of which are located in
he URR of the virus (Li et al., 1989). Two weak E2-binding
ites flank the viral ori, while 4 strong E2-binding sites
hat make up the E2 responsive element, E2RE1, also
lank an E1-binding site (Mendoza et al., 1995; Yang et al.,
991b). The BPV ori is located 89 bp 59 to the P89 viral
RNA start site and is also coincident with the P7940
promoter (Fig. 1A). Transcription from one or both of
these promoters may be affected by E1 binding to the ori,
by replication, or by binding of a multinucleoprotein com-
plex to the site. This possibility is intriguing, since E1
itself may be expressed from one of these promoters.
Although this concept has not been established, it is
known that this cluster of start sites is the most active
promoter region upstream of the E1 ORF in transformed
cells (Baker and Howley, 1987; Choe et al., 1989; Sten-
lund and Botchan, 1990; Stenlund et al., 1985).
Genetic evidence also suggests a role for E1 in mod-
ulating E2 transactivator function. Experiments in which
either the E1 or the E2 gene in the viral genome of
HPV-16 is incapacitated show increased transformation
efficiencies, consistent with the notion that both genes
can negatively regulate, either directly or indirectly, ex-
pression levels of the viral oncogenes E6 and E7 (Ro-
manczuk and Howley, 1992). In HPV-derived cervical
carcinoma cell lines, HPV is usually integrated into the
host chromosome, in a manner that usually disrupts
either the E1 or the E2 gene products, thus leading to
increased levels of viral oncogene expression (Durst etal., 1985; Matsukura et al., 1989; Schneider-Maunoury et
al., 1987; Shirasawa et al., 1988). It is clear, however, that
the transcriptional programs of the genital HPVs and
BPV-1 are not completely analogous. For the major viral
promoters in the BPV-1 case, E2 serves as an activator,
whereas for those human papillomaviruses analyzed, E2
negatively modulates the major promoters (Howley,
1996). It is important to point out that some of the differ-
ences may be more quantitative than qualitative in na-
ture as a report shows that the HPV11 E2 can activate a
major viral promoter at low concentrations of E2 and
switches to a repressor at high levels of protein as more
E2 cis-acting elements are occupied (Chin et al., 1989).
A survey of the BPV-1 literature on the effects of E1
upon E2 activation finds the issue rather unresolved.
Several laboratories have reported genomic mutants in
BPV E1 and E2 that have effects on transformation,
suggesting that replication or transcription, or a combi-
nation thereof, could be involved in regulating the ex-
pression of viral oncogenes. In some reports, E1
genomic mutants show increased transformation effi-
ciency, and significantly higher expression from viral
promoters, when adjusted for template concentration
(Lambert and Howley, 1988; Schiller et al., 1989; Vande
Pol and Howley, 1995). These reports postulate that E1
down-regulates the E2 transcriptional regulatory circuit,
and therefore, its loss of function leads to enhanced
transcription from viral promoters. Other groups have
reported E1 genomic mutants with reduced transforma-
tion capabilities (Chiang et al., 1992a; Lusky and
Botchan, 1985; Sun et al., 1990). In agreement with an
interpretation placing the primary effect of these muta-
tions on viral replication, RNA analysis of mutant viral
genomes transiently expressed in C127 showed no ef-
fect of the E1 mutations on any viral promoters (Szyman-
ski and Stenlund, 1991).
Several reports have also directly addressed the role
of E1 in modulating E2 enhancer function in transient
cell-based assays, although differences in the effect of
E1 on E2 function were again obtained (Ferran and
McBride, 1998; Le Moal et al., 1994; Sandler et al., 1993;
Szymanski and Stenlund, 1991). One group (Szymanski
and Stenlund, 1991) observed no effect of E1 on viral
promoter activity, while another report showed E1 capa-
ble of stimulating E2 enhancer function (Le Moal et al.,
1994), while yet others reported E1 repression of E2
transactivation (Ferran and McBride, 1998; Sandler et al.,
1993). Differences in the cell type and experimental de-
sign have probably contributed to these disparate re-
sults. In addition, a variety of viral nuclear protein com-
plexes can form over the ori region, some perhaps with
different (or opposite) effects on transcription, and the
types of such complexes are determined by the levels of
the E1 and E2 proteins that may vary in different exper-
imental designs.Here we address the role of E1 in E2 transactivation in
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432 PARKER ET AL.an attempt to clarify some of the discrepancies in the
field, to extend our understanding of the role of E1 in E2
enhancer function. As one approach to this problem, a
variety of cis and trans mutants, whose phenotypes in
certain assays have been previously characterized, were
systematically used to elucidate important features in-
volved in E1 modulation of E2 enhancer function.
Employing reporters, some of which were defective for
DNA replication, in a cell-based transient transfection
assay, we determined that E1 does modulate E2 trans-
activator function. Under conditions where E1 stimulates
E2 transactivation, we determined that the E1 DNA-bind-
ing domain was important for stimulation of E2 enhancer
function, although a specific E1 DNA-binding site was
not important for this effect. Through the use of E1
mutants, we found that multiple domains of E1 are re-
quired to stimulate E2 enhancer function. We also pro-
vide evidence consistent with the notion that interactions
between E1 and the E2 activation domain are important
for such synergy between the two viral proteins for tran-
scription function. E1 stimulated E2 enhancer function
when E2 was fused to a heterologous DNA-binding do-
main, although it would not stimulate a heterologous
activation domain fused to the E2 DNA-binding domain.
Furthermore, we show here that E1 rescues E2 activation
domain mutants that are defective for transactivation.
Our data are also consistent with a negative regulatory
role for E1 under certain proscribed conditions.
RESULTS
E1 stimulates E2 enhancer function in bovine embryo
fibroblasts
The role of the BPV replication protein E1 in E2-de-
pendent transcription was addressed using in vivo lucif-
rase assays performed in a bovine embryo fibroblast
BEF) primary cell line. Cells were transfected with a
ixture of DNAs containing the reporter construct URR–
uc, as well as vectors that expressed E2 and E1, from
he heterologous cytomegalovirus (CMV) promoter
Ustav and Stenlund, 1991). An E1 translation construct
ith a termination linker (E1TTL) inserted in the 59 end of
the E1 ORF (Fig. 1A) was used as a negative control for
E1. The reporter, URR–Luc, contains several viral promot-
ers, P7185, P7940, and P89, the BPV ori, the major enhancer
element E2RE1, and many other previously characterized
E2-binding sites that make up the URR (Haugen et al.,
1987; Li et al., 1989; Spalholz et al., 1985, 1987) fused to
the firefly luciferase gene. Transfection of the reporter
and E2 alone demonstrated that E2 could stimulate tran-
scription from this reporter construct. Light activity of
URR–Luc transfected with E2 was approximately 4.8 ar-
bitrary light units compared to 0.01 light units obtained
with URR–Luc alone. As shown in Fig. 1B, increasing the
amounts of pCG-E1 transfected into cells containing 250
ng of the URR–Luc and 50 ng of pCG-E2 increased theluciferase activity as measured in arbitrary light units,
showing up to eightfold stimulation of light activity over
that obtained with E2 alone. A similar titration of the
control expression vector, pCG-E1TTL, resulted in no
stimulation of light activity over E2 stimulation alone.
Only 0.02 arbitrary light units of luciferase activity were
obtained from cell lysates when either pCG-E1 or pCG-
E1TTL was transfected into cells with the reporter plas-
mid alone (data not shown). These data indicate that E1
specifically stimulates E2-dependent transcription from
the URR–Luc reporter, but is not, by itself, acting as a
transcription factor. These gene expression results were
further substantiated by extraction of total RNA from
transfected cells and direct primer extension analysis
(Fig. 1C). The P2CAT reporter construct was used (Sten-
lund and Botchan, 1990) instead of URR–Luc, due to
increased stability of the message. We found that the P89
promoter was indeed activated by E1, being readily de-
tected only when E1 and E2 were coexpressed.
URR–Luc, which contains the BPV ori, replicates in the
presence of both E1 and E2 in BEF cells (data not
shown). Thus, the increase in luciferase activity could
have been due to amplification of the reporter template,
rather than to a direct effect of E1 on E2 enhancer
function. Therefore, we asked whether the stimulation of
transcription could be seen in the absence of replication
by using a reporter construct, E2RE1tk-Luc, incapable of
replication. Although E2RE1tk-Luc contains both E1- and
E2-binding sites, as determined by DNA protein coim-
munoprecipitation experiments and DNase 1 protection
experiments (Mendoza et al., 1995; Mohr et al., 1990), it
does not replicate in vivo as it contains no bona fide ori
(data not shown).
E2 stimulated transcription from this reporter, giving a
light activity of 30 arbitrary light units in this experiment,
while in the absence of E2, light activity from reporter
alone was about 0.3 light units. The presence of pCG-E1
or pCG-E1TTL did not significantly affect this basal re-
porter activity in the absence of E2 (data not shown). A
titration of increasing amounts of pCG-E1 transfected
with 50 ng of pCG-E2 and 250 ng of E2RE1tk-Luc re-
sulted in an increase of light activity, about sevenfold,
over that seen with E2 alone (Fig. 1D). As a comparison,
no detectable increase in light activity was seen when
pCG-E1TTL was titrated in the presence of E2 expres-
sion vector and reporter. Although the overall activity of
the E2RE1tk-Luc reporter was higher than that seen with
URR–Luc, both in the presence and in the absence of E2,
qualitatively, the results are thus similar. The stimulation
by E1 of E2-dependent gene expression from these two
reporter constructs indicates that replication of the URR–
Luc reporter does not significantly contribute to the stim-
ulatory effect of E1 on E2 enhancer function. Other ex-
periments, described later, further substantiate the point
that replication is not a significant factor in E1 stimulation
of E2 enhancer function.
U
7
t
U
a
w
m
5
c of bot
script.
433BPV E1 MODULATES E2 ENHANCER FUNCTIONStimulation of E2 transactivation by E1 is dependent
on reporter concentration
Variables were sought that might explain some of the
discrepancies between the different published reports
and the data presented here. One difference between
the different reports was the concentration and type of
reporter construct used. Because both E1 and E2 are
DNA-binding proteins that interact with each other and
DNA as multimers, reporter concentration and thus the
effective protein-binding site ratio could play a critical
role in the effect of E1 on E2 enhancer function. This is in
part because the E2 transactivator function is synergistic
and E2 dimers bound to multiple E2-binding sites up-
FIG. 1. (A) Schematic of the upstream regulatory region. URR of BPV
box and oval) at the enhancer element E2RE1 and the BPV ori (oval). V
are located proximal to the binding sites in the BPV ori and upstream of
RR luciferase contains BPV sequences from 6958 to 100 nt upstream
598–7831 upstream of the minimal thymidine kinase gene promoter up
ransfected with 50 ng of pCG-E2 and increasing amounts of pCG-E1 (
RR–Luc reporter or the nonreplicating E2RE1tk-Luc reporter (D). Cel
ctivity as described elsewhere. Experiments were done in duplicate a
as performed with total RNA isolated from BEF cells 2 days aft
ock-transfected cells. Lanes 2 through 6 were transfected with 250 n
0 ng pCG-E2 as well as 5 mg pCG-E1, lane 5, with 50 ng pCG-E2 a
orresponding to the predicted size of P89 can be seen in the presence
shown on the right, to identify the 59 extension product of the P89 transtream of a promoter have significantly greater ability tostimulate transcription than does a single E2 dimer
bound to a site upstream of a promoter (Li et al., 1991).
To address the potential role of reporter concentration
on E1 stimulation of E2 enhancer function, transfections
in BEFs were performed in which the levels of E1 and E2
expression vector DNAs were held constant, while the
amount of the reporter varied. Experiments were per-
formed with 50 ng of pCG-E2 and 1 or 5 mg of pCG-E1 (5
mg shown) or pCG-E1TTL as a negative control. These
expression vectors were transfected into cells with in-
creasing amounts of the URR–Luc reporter construct,
and reporter gene activity was measured. The level of E1
stimulation of E2 enhancer function was typically high at
s E2 binding sites (black boxes) flanking the E1-binding sites (striped
moters P7185, P7940, P89, and P890 are depicted with arrows. P7940 and P89
RF, which begins at nucleotide 813. P890 is within the E1 coding region.
luciferase gene, while E2RE1tk-luciferase contains BPV nucleotides
of luciferase. (B) Depicted is a representative experiment of BEF cells
e) or E1TTL (broken line) in the presence of 250 ng of the replicating
electroporated and harvested after 48 h and assayed for luciferase
um of three times. (C) Primer extension analysis of P2CAT transcripts
troporation. The P89 extension product is denoted. Lane 1 shows
T. Lane 3 was additionally transfected with 50 ng pCG-E2, lane 4, with
g pCG-E1TTL, and lane 6 with pCG-E1. A primer extension product
h E2 and E1. A sequencing ladder of P2CAT using the same primer iscontain
iral pro
the E1 O
of the
stream
solid lin
ls were
minim
er elec
g P2CA
nd 5 mlow reporter concentrations (see inset, Fig. 2A). As re-
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434 PARKER ET AL.porter concentration is increased, stimulation of tran-
scriptional activation is reduced in the presence of E1
expression, with repression of E2 transactivation being
detected at very high reporter concentrations (Fig. 2A). A
graph of the E1 fold stimulation clearly depicts this trend
(see Fig. 2B). E1 fold stimulation is maximal at the lowest
reporter concentrations used, and the fold stimulation
decreases as the reporter concentration is increased.
Thus at high levels of reporter, E1 expression does in-
deed repress E2 activation. Similar results were obtained
with the nonreplicating E2RE1tk-Luc reporter (data not
shown). The repression we see at high reporter concen-
trations is consistent with published reports document-
ing E1 repression; however, the magnitude of the effect
is not as dramatic (2- to 5-fold compared to 10- to 20-fold)
FIG. 2. E1 modulates E2 enhancer function in a reporter concentra-
tion-dependent manner. In a representative experiment, 50 ng of
pCG-E2 and 5 mg of pCG-E1 (solid lines) or E1TTL (broken lines) was
transfected into cells with increasing amounts of the URR–Luc reporter
(A and B). Duplicate points are depicted. Reporter gene expression is
measured in arbitrary light units. The inset in A is an expansion of the
data at low reporter concentrations. Graph of the fold effect of E1 on E2
transactivation is depicted in (B). Fold effect was determined by graph-
ing the ratio of average light activity obtained from the duplicate
samples at each concentration of reporter of E2 1 E1/E2 1 E1TTL.(Sandler et al., 1993).This variation of E1’s effect on E2 enhancer function in
response to reporter concentration perhaps explains
some of the discrepancies in the literature. Why does
such reporter concentration dependence exist? It is
known that E1 and E2 bind DNA cooperatively and that
E2 stimulation of transcription is optimal when E2 acts as
a multimer. Cooperative interactions between E1 and E2
may enhance E2 activity at low reporter concentrations,
as the relative affinity of E2 for DNA is increased due to
the presence of E1. In the presence of high reporter
concentrations, E1 may have a distributive effect, bring-
ing E2 to bind to too many different reporter molecules in
the cell. This generalized distribution of E2 may effec-
tively reduce the ability of E2 to multimerize, which may
result in an apparent repression of transcription at high
reporter concentrations.
E1 binding to a specific site is not required for
stimulation of E2 enhancer function
We used previously characterized mutations in the
BPV URR that disrupt E1 DNA binding to determine the
role of specific E1-binding sites on E2 enhancer function.
A series of E1-binding site mutations within the BPV ori
and within E2RE1 were constructed in the URR–Luc
reporter construct. For the 5C-20C series, linkers of in-
creasing length in steps of 5 bp were inserted at the ori
alindrome and the others are simple deletion muta-
ions. Another reporter (d60dOpal) was employed, con-
aining a double mutant that eliminated E1-binding sites
oth in the ori and in E2RE1, which are absent in this
onstruct. Previous studies demonstrated that mutations
n these two regions severely alter, or eliminate, the E1
NA footprints on these regions (Mendoza et al., 1995).
hese studies also demonstrated that in vivo, the ori
inker insertion mutants were severely impaired for rep-
ication, while the ori deletion mutant (dOpal) completely
abolished replication in vivo.
These mutant reporters were tested, under conditions
in which E1 stimulates E2 enhancer function, to deter-
mine whether E1 would stimulate E2-dependent tran-
scription in the absence of a known E1-binding site.
Basal expression from these reporters was measured
and was consistently low, with an average luciferase
activity of 0.2 light units. Furthermore, pCG-E1 and pCG-
E1TTL had no discernible effect on reporter light activity
in the absence of E2 (data not shown). E2 activation of
these reporters in the absence of E1 was slightly vari-
able; notably, the ori linker insertion mutant 20C URR–
Luc consistently exhibited lower activation by E2 than did
the wild-type URR–luc reporter (by about half). The in-
creased distance of the ori proximal E2-binding sites to
one another may be responsible for this difference in
transcriptional activity. E1 stimulated E2-dependent
transactivation from each of these reporters. The data
presented are averaged from 6–10 independent experi-
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435BPV E1 MODULATES E2 ENHANCER FUNCTIONments (Fig. 3A). Mutations in the E1-binding sites, includ-
ing the double deletion mutant d60dOpal URR–Luc, had
no effect on the ability of E1 to stimulate E2 enhancer
function. The ori linker insertion mutants, as well as
dOpal, the ori deletion, show significantly reduced levels
of replication (Mendoza et al., 1995), while they all be-
FIG. 3. An E1-binding site is not required for its stimulation of E2
enhancer function. (A) 50 ng of pCG-E2 was transfected into BEF cells
in the presence of 5 mg of pCG-E1 or E1TTL with 250 ng of the wild-type
or mutant URR-Luc reporter (as noted in graphs). 5C, 10C, 15C, and 20C
are linker insertions at the BPV ori and dOpal is a deletion of the BPV
ori. S1, P1, and S2 are substitution mutations of the E1-binding site in
E2RE1, while d60 deletes the 60-bp element of E2RE1 where E1 foot-
prints (Mendoza et al., 1995). The stimulation of E1 on E2 enhancer
unction was determined by dividing E2 1 E1/E2 1 E1TTL for each
utant and is graphed here as fold stimulation. These data represent
he average of 6–10 independent electroporations, each done in dupli-
ate, and error bars represent 1 standard deviation. Depicted is the fold
timulation of E2 enhancer function by E1 of wild-type URR–Luc (striped
olumn), origin mutant reporters (gray columns), E2RE1 mutant report-
rs (hatched columns), and a double deletion lacking E1-binding sites
n both regions (black column). (B) Titrations with increasing amounts
f pCG-E1 (open circles and squares) or pCG-E1TTL (filled circles and
quares) performed in the presence of 50 ng of the E2 expression
ector and 250 ng of the wild-type (solid lines and squares) or
60dOpal-mutant (broken lines and circles) URR–Luc reporter. Similar
esults were obtained from three additional independent experiments.have equivalent to wild type in our assays here. Together,these data demonstrate that E1 stimulates E2 enhancer
function in the absence of a specific E1-binding site.
In the analysis of E1 stimulation of E2 transactivation
described above, the concentrations of the E1 expres-
sion vector used to compare the phenotypes of different
cis mutants in the URR–Luc reporter were those that
gave maximal effects, as determined by our initial titra-
tion experiments. It has been reported that the in vitro
E1-binding affinity to nonspecific DNA is only 10- to
100-fold lower than its binding to specific DNA se-
quences (Sedman and Stenlund, 1996). It was thus pos-
sible that saturating amounts of E1 were able to obscure
the potential role of a specific E1-binding site in regulat-
ing E2 enhancer function. To test this possibility, titra-
tions were performed in vivo with increasing amounts of
pCG-E1 and the total expression vector concentration
was held constant, with E1TTL added to adjust for
changes in the concentration of the E1 expression vec-
tor. The URR–Luc and the double deletion mutant
(d60dOpal) were used as reporters in this analysis.
E1 stimulation of the wild-type reporter luciferase ac-
tivity, URR–Luc, increased in a monotonic way with in-
creasing E1 expression vector transfected into cells in
the presence of E2. Similar increases were seen when
E1 was titrated with the double E1-binding site deletion
reporter, d60dOpalURR-Luc (Fig. 3B). Thus, the E1 site
deletion mutant had no significant effect on E1 stimula-
tion of E2 enhancer function at any concentration of E1
used relative to the wild-type reporter, and even at sub-
saturating levels of E1, specific E1-binding sites are not
required to mediate E1 stimulation of E2 enhancer func-
tion.
Multiple domains of E1 are required for cooperative
interactions with E2
We were interested in correlating any known functions
of E1 with its ability to stimulate the E2 enhancer function
using our transient transcription assay. To do this we
took advantage of several well-characterized mutants of
E1 that perturb the DNA-binding, cooperative DNA-bind-
ing with E2, ATP-binding, or ATP hydrolysis activities of
E1.
Several of our previously characterized DNA-binding
domain mutants, LPM3 (P266A, I268A, L275A), LPM4
(K241A, R243A), and LPM6 (R180A), are reduced sub-
stantially in their ability to bind an ori-containing frag-
ment of DNA both in the presence and in the absence of
E2. LPM1 (L275P) binds better than wild-type E1 in vitro,
in the presence of E2, but its DNA binding is reduced in
the absence of E2. LPM5 (R247A) binds DNA at signifi-
cantly reduced levels from wild-type E1, both in the pres-
ence and in the absence of E2; however, its ability to bind
DNA is stimulated by E2, albeit to a lesser extent than
wild-type E1. A deletion mutant (d50) that deletes amino
acids 250 to 300 of E1, part of the core region of the E1
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436 PARKER ET AL.DNA-binding domain, has also been shown to be incom-
petent to bind DNA in vitro. Only one of these mutants,
LPM5, is competent for replication (about 30% of wild-
type levels), although all are expressed well in vivo (Thor-
ner et al., 1993).
Three E1 ATPase domain mutants, KE439, DA497, and
HL507, were also assayed for their ability to stimulate E2
transcription. These mutants bind ATP at significantly
reduced levels, are unable to hydrolyze ATP, and are
unable to replicate a BPV ori-containing plasmid in vivo
although they are, with the exception of KE439, similarly
expressed (MacPherson et al., 1994) and have been
reported to bind DNA better than wild-type E1 (Thorner et
al., 1993).
These DNA-binding and ATPase mutants of E1 were
tested for their ability to stimulate E2-dependent tran-
scription in vivo. These E1 mutants had no effect on
reporter activity in the absence of E2 (data not shown).
We found that only one mutant, LPM5, is able to stimulate
E2 enhancer function to nearly wild-type levels from both
the replication-competent URR-Luc reporter (data not
shown) and the non-replication-competent E2RE1tk-Luc
reporter (see Fig. 4). These data are consistent with the
notion that an intact DNA-binding domain of E1 is re-
quired to stimulate E2-dependent transcription, as all of
the mutants that fail to bind DNA alone and in coopera-
FIG. 4. Multiple domains of E1 are required to stimulate E2 enhancer
unction. 50 ng of pCG-E2 was transfected into BEF cells with 250 ng
2RE1tk-Luc reporter and 5 mg of wild-type or mutant E1 expression
ectors as indicated, except for the far column, which contains reporter
lone as a negative control. DNA-binding mutants (striped columns)
nd ATP mutants (gray columns) that fail to stimulate E2 are compa-
able to E2 1 E1TTL or E2 alone (crossed columns) in their luciferase
ctivity. LPM5, which has replication activity in vivo, is able to stimulate
2 in transactivation, although E2RE1tk-Luc does not replicate in vivo.
imilar results were obtained from six additional independent electro-
orations, as well as six independent electroporations using 1 mg of
he E1 expression vectors.tion with E2 are also defective in this assay. Interestingly,LPM5 binds weakly to DNA on its own, but E2 can
rescue its function in cooperative DNA-binding assays in
vitro as well as rescue its replication function in vivo
(Thorner et al., 1993). These data also demonstrate that
the carboxy-terminal domains of E1 important for heli-
case and replication functions are also required for such
stimulatory activity.
E1 stimulation of transcription shows specificity for
the E2 transactivation domain
Several studies have demonstrated that the BPV-1 E2
activation domain is important for interacting with E1 and
that such interactions were important for replication (Lim
et al., 1998; Winokur and McBride, 1992). We were inter-
ested in determining whether the E1 stimulation of E2
enhancer function required the E2 activation domain.
Alternatively, the E1 stimulation we observe could be due
to its ability to recruit a cellular factor to a complex
important for transcription. E1 has been shown to inter-
act with DNA polymerase, and no evidence precludes its
interaction with components of the general transcrip-
tional machinery or with factors important for both repli-
cation and transcription.
We took advantage of the modular nature of the E2
transcription factor to address the role of specific E1:E2
interactions in the E1 stimulation of E2 enhancer func-
tion. We fused the E2 activation domain and hinge region
(amino acids 1 to 325) to the amino-terminal DNA-bind-
ing domains of the tet repressor (tetR), to test the ability
of this fusion protein to stimulate transcription and be
activated by E1. We used a VP16–tetR fusion construct in
comparison. In mammalian cell culture, eukaryotic acti-
vation domains, when fused to tetR, can activate tran-
scription from promoters containing tet operator sites in
a tetracycline-dependent manner (Gossen and Bujard,
1992).
Both the E2–tetR fusion and the VP16–tetR fusion were
able to stimulate transcription from a reporter containing
tet operator-binding sites, as measured by the luciferase
activity. Expression vectors for each fusion protein were
transfected into BEF cells with the tet-operator reporter
construct as well as pCG-E1TTL as a negative control.
After transfections, the cells were incubated in the pres-
ence or in the absence of tetracycline. The stimulation of
luciferase activity detected in these assays was depen-
dent on tet-repressor DNA binding, as the same con-
structs failed to stimulate transcription when tetracycline
was present in the cell culture medium.
E1 stimulation of the activity of either of these fusion
constructs in the presence or in the absence of tetracy-
cline was tested. Cells were transfected as described
above, with the addition of pCG-E1. As shown in Fig. 5A
(black columns), E1 stimulated the enhancer function of
the E2–tetR fusion protein, but not the VP16–tetR fusion.
This E1 stimulation of E2 enhancer function was not
t
a
expression vector, consistent with previously characterized pheno-
types. (C) The fold stimulation of mutant or wild-type E2 trans-
437BPV E1 MODULATES E2 ENHANCER FUNCTIONseen when the E2–tetR fusion protein is unable to bind
DNA (in the presence of tetracycline). These data sug-
gest that direct interactions between the E2 activation
domain and E1 are important for E1 stimulation of E2
enhancer function.
E1 rescues the enhancer function of a
transcriptionally defective E2 mutant
Mutational analysis of the E2 activation domain and
DNA-binding domain has been performed by several
groups. Several point mutants in the E2 activation do-
main were made, some of which were found to geneti-
cally separate the functions of E2 (Abroi et al., 1996;
Brokaw et al., 1996; Ferguson and Botchan, 1996; Gros-
sel et al., 1996); in one mutant the replication function
was retained while transcription was reduced, and in
another mutant the reverse was found. Mutants in the
DNA-binding and dimerization domain of E2 have also
been made. One of these mutants, W360N, is unable to
dimerize and as a consequence fails to bind DNA. Other
mutants in the DNA-binding domain, 339M, 340F, and
344L, are able to dimerize, but they bind DNA at signif-
icantly reduced levels (Prakash et al., 1992); conse-
quently, these mutants are impaired for their ability to
stimulate transcription and replication (Li et al., 1994;
Prakash et al., 1992). By using these point mutants we
hoped to address whether the ability of E1 to stimulate
E2 enhancer function correlated with the ability of E2 to
stimulate replication and furthermore, to determine
whether the cooperative interactions between E1 and E2
could rescue E2 point mutants.
As shown in Fig. 5C, E1 is unable to rescue mutants of
E2 that are defective for DNA binding. These mutants
show reduced transcription in the presence and in the
absence of E1. A fusion construct, VP16–E2, that contains
the VP16 activation domain fused to the E2 DNA-binding
domain stimulated transcription; however, E1 had no
effect on the enhancer function of this fusion protein
(Figs. 5B and 5C). These data suggest that the primary
effect of E1 on E2 enhancer function occurs through
interactions with the E2 activation domain. Thus, al-
though E2 DNA binding is necessary for this effect, a
specific E2 DNA-binding domain is not required, since
an E2–tetR fusion construct is also able to be stimulated
by E1.
E1 could stimulate the enhancer function of several
activation domain mutants. IN73 and IA73, two mutants
that function as wild type in DNA replication but are
defective for transcription, are actually rescued in their
ability to function as transcriptional enhancers by E1.
activation by E1 was determined by dividing light activity of E1 1 E2FIG. 5. E1 requires the E2 activation domain to stimulate enhancer
function. (A) 50 ng of the E2-tetR and VP16-tetR activation domain
fusion constructs was transfected into BEF cells with 250 ng of the
tet-Luc reporter and 5 mg of pCG-E1 or pCG-E1TTL. Cells were
ransfected and incubated in the presence (1tetracycline) or in the
bsence (2tetracycline) of 1 mg tetracycline/ml in the cell culture
medium. Fold effect of E1 on activation domain fusion constructs
was then determined by dividing fusion 1 E1/fusion 1 E1TTL. These
data are representative of six independent electroporations. Error
bars represent 1 standard deviation. (B) 250 ng of the URR–Luc
reporter was electroporated into cells with 50 ng of the wild-type or
mutant pCG-E2 and 5 mg of pCG-E1 or E1 TTL. Luciferase activity
was assayed in cell extracts harvested 2 days after transfection.
Stimulation of reporter gene expression varied dramatically among
the various E2 mutants transfected with E2 and the E1TTL controlconstruct/E1TTL 1 E2 construct. Fold stimulation was an average of
eight independent experiments.
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438 PARKER ET AL.Additionally, E1 could stimulate the activity of another E2
activation domain mutant, EA39. EA39 stimulation of
transcription is similar to wild type; however, its ability to
stimulate replication in vivo is impaired (Ferguson and
Botchan, 1996). This result indicates that though E1 does
not productively interact with EA39 for DNA replication,
interactions for transcription can be indirectly assessed.
Perhaps E1:E2 interactions for transcription are less
stringent than are those required for DNA replication.
Figure 5C shows a quantitation of the fold induction
effected by E1 upon these mutants. We suggest that E1
may in some way modulate the structure of the E2
activation domain, perhaps stabilizing a particular con-
formation of E2 that enhances the factor’s ability to act as
an enhancer protein. Along these lines it is interesting to
point out that many of the mutants in the E2 activation
domain are temperature sensitive. IN73 and IA73, for
example, are wild type in their transactivation function at
reduced temperatures (Ferguson and Botchan, 1996). E1
may stabilize an active conformation for IN73 and IA73 in
much the same way that reduced temperature seems to
stabilize these proteins.
CONCLUSIONS
In this report, we demonstrate that the papillomavirus
E1 protein plays a role in modulating the enhancer func-
tion of transactivator E2, in vivo. Other reports have
imilarly addressed the role of E1 in modulating E2
nhancer function. A key conclusion from our results is
hat reporter concentration influences the sign of this
odulation. E1 stimulated E2-dependent transcription at
ow reporter concentrations, and this stimulation de-
reased with increasing concentrations of reporter, with
1 repression of transcription being observed at the
ighest reporter concentrations used. The repression by
1 of E2 function reported by Sandler et al. (1993) in BEF
ells is consistent with our results at high reporter con-
entrations; however, the magnitude of repression was
ess in our data and we find no requirement for an
1-binding site for E2 stimulation. It is possible that other
ariations in the reporters, cell lines, and transfection
onditions used contributed to these differences. Along
hese lines, we found that E1 had no effect upon E2
nhancer activity in C127 cells, though synergistic posi-
ive activity was indeed found in HeLa and C33A cells,
hile in CV-1 cells only repression was detected at the
ighest levels of reporter (Parker, 1996). The repression
e see at high reporter concentrations is more consis-
ent with the observations reported by Le Moal et al.
1994). In that report repression was ascribed to
squelching” caused by the extremely high levels of ex-
ression vectors and reporter plasmids transfected into
he cells. Results of Ferran and McBride (1998), which
how similar effects of E1 mutants that are compromisedor DNA binding on repression of E2 enhancer function,ay also be consistent with E1 repression caused by
ither squelching or partitioning of active E2 away from
he reporter to the large amounts of bacterial plasmid
arrier DNA with weak E2 sites (Lim et al., 1998) used in
heir experiments. Thus according to our hypothesis, at
ow levels of reporter concentrations, E2 and E1 site
oncentrations are such that cooperative interactions
etween E1 and E2 allow for loading of a starting E2:E1
omplex onto DNA. This complex then may allow for
ubsequent loading of multiple E2 molecules to tandem
is-acting E2 sites on the reporter. This in turn results in
aximal transcriptional activity. At higher levels of cis-
cting sites, one may suppose that E1 loads many E2
imers to too many different molecules, leading to a
ituation wherein not enough E2 (or other trans activity
actors) can build an effective enhanceseosome.
Though BPV-1 requires the E1 inverted repeats for
ffective DNA replication in vivo, certain data show that
he E1 protein can productively interact with nonspecific
NA. Furthermore cooperative DNA binding between E1
nd E2 for transcription may have a less stringent re-
uirement for E1-binding sites than for in vivo replication
omplexes. E1 has been shown to unwind and replicate
NA in an ori-independent fashion in vitro (Fouts et al.,
999; Yang et al., 1993), and for BPV replication, in vivo
trong E2-binding sites compensate for mutations in the
ri E1-binding site (Sedman and Stenlund, 1995). Further-
ore, mutational analysis of certain serotypes of HPV ori
egions shows a stronger dependence on E2-binding
ites for replication efficiency than E1, suggesting that
he specificity of binding may be due to HPV E2 cooper-
tively binding E1 (Chiang et al., 1992b; Remm et al.,
992; Russell and Botchan, 1995). The requirements for
he DNA-binding domains of E1 for E2 activation may
hus be naturally expected for both nonspecific and spe-
ific protein DNA complexes mediated by this factor.
Cooperative interactions on DNA are likely to be im-
ortant for E1’s ability to stimulate E2 transactivation. It
as been established that the BPV E1 protein interacts
ith full-length E2 and that these interactions are impor-
ant for the replication of BPV ori-containing plasmids in
ivo and in vitro (Li and Botchan, 1993, 1994; Lim et al.,
1998; Ustav and Stenlund, 1991; Yang et al., 1991a).
Based on our findings, it is reasonable to postulate that
these interactions are similarly important for the effects
of E1 on E2 enhancer function. However, our analysis of
activation domain mutants of E2 in this assay leads us to
suggest that cooperative DNA binding does not by itself
explain E1’s stimulation of E2 enhancer function. We
found that E1 could rescue the enhancer function of E2
activation domain mutants defective for transcription in
vivo. For example, the E2 mutant IN73 shows less than
1% of E2 activity, but in the presence of E1, transcription
reporters yield activities close to wild-type E2 levels. This
result indicates a function for E1 beyond a tethering
activity, for IN73 binds to DNA with wild-type affinity.
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439BPV E1 MODULATES E2 ENHANCER FUNCTIONBecause E1 is unable to stimulate the enhancer function
of a heterologous activation domain, we favor a model in
which E1 enhances or stabilizes a transcriptionally “ac-
tive” conformation of E2, which then could potentially
allow more productive interactions with cellular factors
important for transcription. However, our results do not
rigorously prove that the effects of E1 are due to direct
protein:protein interactions between E1 and E2. Indeed
Demeret et al. (1998) have presented data that indicate
hat E1 may contain cryptic transcriptional activation
egions and that these may be targeted to DNA or en-
anced by E2. At present this later thought and other
ven more complicated models cannot be ruled out, but
e note that Demeret et al. (1998) required multiple
tandem cis elements to detect weak E1 transactivation
nd that in our data E1 by itself showed no transactiva-
ion. Thus our model can simply explain the current data
ith the viral URR.
In transcription complexes many proteins exert allo-
teric or stabilizing effects on other proteins that alter or
nhance activity. For example, the transcription factor
TF-2 is thought to be activated by the adenovirus E1a
hrough stabilization of a particular conformation. The
ZIP domain of ATF-2 is thought to be masked in vivo
hrough direct interaction between the bZIP domain and
n N-terminal zinc finger (Abdel-Hafiz et al., 1993). Asso-
iation with E1a exposes this domain, allowing transcrip-
ional activation.
Our data may also be consistent with the notion that
1 cooperative interactions with E2, including allosteric
ffects on the activation domain, may facilitate interac-
ions between E2 and a cellular factor. Interactions with
his cellular factor could be very weak in transcriptionally
ompromised E2 mutants, and E1 may be able to rescue
hese mutants by stimulating the interactions between
2 and a cellular factor. Both E1 and E2 interact with a
ariety of cellular replication and transcription factors
Benson et al., 1997; Bonne-Andrea et al., 1995; Cueille et
l., 1998; Li et al., 1991; Park et al., 1994; Rank and
Lambert, 1995).
We suspect that one form of a DNA replication preini-
tiation complex involving E1 and E2 is responsible for the
enhanced transcription activity detected. This because
E2 has been found to leave such complexes in an ATP-
dependent step prior to double hexamer formation and
we assume that E2 must therefore function prior to its
release (Lusky et al., 1994; Sanders and Stenlund, 1998).
In this regard it is curious that mutants in the E1 ATP-
binding domain are defective in transactivation activity.
Given that E2 is likely to interact with a rather large
surface of E1 including regions in the DNA-binding do-
main and the carboxy-terminus of the helicase initiator,
one might posit that ATP binding per se is not critical for
transactivation but rather the native conformation of this
domain is critical. E1 ATP binding and multimerization
may thus be processes that compete with a stable E1:E2 tcomplex in cis on the ori sites. The recent crystal struc-
ture of a human form of the E2 activation domain (Harris
and Botchan, 1999) shows that the surface has multiple
and scattered regions important for replication and tran-
scription. Furthermore, flexible surface loops of E2 are
found that might be expected to change conformation
upon interaction with E1. It will clearly be important to
obtain further mutational and structural analyses of the
E2:E1 interaction domains to test the idea that E1 might
transiently stabilize a transcriptionally active form of E2.
What roles may the enhancer-modulating activities of
E1 play in the viral life cycle? Here, we are particularly
intrigued by the possibility that P89 activity is enhanced
by E1 protein and that this process is autocatalytic. After
increased E1 levels occur, one may expect DNA ampli-
fication and subsequent repression of both the P89 and
he P7940 promoters to manifest perhaps a down-modu-
ation of the viral replicon by simple titration of the E2
rotein by mechanisms discussed above.
MATERIALS AND METHODS
lasmids
Wild-type and mutant BPV E1 and E2 proteins were
xpressed from plasmids containing the CMV promoter
n the plasmid pCG-ATG2 as described by Tanaka and
Herr (1990). The pCG-E2 and pCG-Eag expression vec-
tors, which make the BPV E2 and E1 gene products,
respectively, have been previously described (Ustav and
Stenlund, 1991), as have the expression vectors that
make the E1 DNA-binding and ATP-binding mutants
(MacPherson et al., 1994; Thorner et al., 1993), the E2
activation domain and DNA-binding domain mutants
(Ferguson and Botchan, 1996; Prakash et al., 1992), and
the VP16–E2 and VP16–tetR fusion proteins (Gossen and
Bujard, 1992; Li et al., 1991). The E1TTL mutant pCG-
E1TTL was constructed by inserting a translation termi-
nation linker into the SmaI site at E1 nucleotide 945.
E2–TetR fusion genes were made by cloning PCR
products of E2 into pUHD14-1Sma (Baron et al., 1997)
ncoding the Tet repressor (Baron et al., 1997). PCR
roducts were made using the primer E2TF5 at the 59
nd of E2 (59CCC GAA TTC CCG GGG GGT GCC ATG
AG ACA GCA TGC GAA C) and the E2TF3L primer
59CCC GGA TCC TTA TCT AGA CCC CCC TCC TGC CTT
AA CAG) at the 39 end of E2 to encode the first 325
mino acids of E2. The 59 primer has EcoRI and XmaI
ites engineered at the 59 end of the primer, and the 39
rimers contain engineered BamHI and XbaI sites at the
9 end of the primer. The E2 activation domain was
loned upstream of the Tet repressor DNA-binding do-
ain using EcoRI and XbaI to generate fusion proteins.
ll fusion proteins are expressed from the CMV pro-
oter.
The reporter plasmid pUHC13-3, containing tet opera-or sites upstream of the minimal CMV, has been de-
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440 PARKER ET AL.scribed previously (Gossen and Bujard, 1992). The
EcoRI-BsaI backbone fragment from the pUHC131-1 lu-
ciferase (Bonin et al., 1994) and the EcoRI–BsaI fragment
from the URR containing pH100 (Lusky and Botchan,
1984) were fused together via ligation to create URR–Luc.
A BglII–PflmI fragment from the pT81 luciferase contain-
ing plasmid (Nordeen, 1988) and a BglII–PflmI fragment
from the E2RE1tk-CAT reporter were ligated together to
create the E2RE1tk-Luc reporter. E2RE1tk-CAT was con-
structed through a ligation of a HindIII-blunted Nde1
vector fragment from the plasmid pBLCAT, derived from
the 237tkCAT plasmid (Luckow and Schutz, 1987), to a
SmaI–HindIII fragment of the fragment UR229. UR229
contains E2RE1 from nucleotides 7598 to 7831 cloned
into the pUC18 polylinker through a sticky/blunt ligation
of the BamHI–BglII BPV fragment to the BamHI–HincII
sites in the pUC18 polylinker.
The mutant URR–Luc reporter plasmids were con-
structed using the following strategy. PCR products con-
taining wild-type or mutant oris were engineered with the
59 7805 primer (59-GCTCGAAACCGCCTTAAAC-39) and
the 39 22 primer (59-CTCGAATTCAGGTCCATGTG-39),
which has an engineered EcoRI site. All mutant origins
have been previously described (Mendoza et al., 1995).
The PCR products containing wild-type or mutant oris
were cut with BglI and EcoRI and ligated to a MluI–BglI
insert containing a wild-type or mutant E2RE1 region of
the BPV genome and a MluI–EcoRI vector fragment of
URR–Luc. All constructs were subsequently sequenced
to confirm that mutant constructs had been obtained.
Plasmid clones and PCR products were made using
standard protocols (Sambrook et al., 1989).
Cell culture
Primary BEFs, kindly provided by Barbara Spalholz
(National Institutes of Health), were grown in 10-cm
plates until 80% confluent. Cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with
10% fetal calf serum, 100 mg/ml streptomycin, and 100
U/ml penicillin. Cells were trypsinized and diluted 1:5 to
passage them. These cells were never used after pas-
sage 12. For studies using tet fusion constructs, inacti-
vation was achieved by incubation of cells with cell
culture medium containing 1 mg tetracycline per milliliter
of medium, immediately posttransfection.
Transfections
Transfections were done using electroporation, essen-
tially as previously described (Ustav and Stenlund, 1991).
Briefly, cells were split 24 h prior to electroporation, and
2–5 3 106 actively growing cells were trypsinized and
pooled. Cells were resuspended in 0.25 ml Dulbecco’s
modified Eagle’s medium with 10% fetal calf serum and 5
mM N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid
(pH 7.2). The DNA samples, as described in the figurelegends, were mixed with 25 mg of sheared salmon
sperm DNA and the 0.25-ml cell suspension. This mix-
ture of cells and DNA was then transferred to an elec-
troporation cuvette (0.4-cm gap Bio-Rad Gene Pulser
Cuvettes). Cells were electroporated at 250 V at a ca-
pacitance of 960 mF with a Bio-Rad Gene Pulser. Cells
ere then removed from the cuvette and aliquotted into
ne or two 60-mm plates and harvested after 48 h. Due
o the effects of E2 on a variety of heterologous promot-
rs (Haugen et al., 1988; Parker and Botchan, unpub-
lished observations), no internal controls could be used
for normalizations of transfection efficiencies. All exper-
iments were done in duplicate and were repeated a
number of times to ensure reproducibility.
Luciferase assays
Cells were harvested from 60-mm plates using 500 ml
of a buffer containing 0.5% Tween 20, 2 mM CDTA, and
25 mM bicine, pH 7.8. Plates with the lysis buffer were
frozen at 280°C for no less than 30 min. Plates were
thawed and the lysates were used directly or refrozen at
280°C until assayed, and samples were spun in a mi-
crofuge for 10 s to bring down cellular debris. Luciferase
assays were performed using the continuous count
method outlined by Promega Technical Bulletin 480 (Pro-
mega, 1993). Essentially, 100 ml of the luciferase assay
reagent containing 20 mM Tricine, pH 7.8, 1.07 mM
(MgCO3)4Mg(OH)2 z 5H2O, 2.67 mM MgSO4, 0.1 mM
EDTA, pH 7.8, 33.3 mM DTT, 270 mM Coenzyme A, 470
mM luciferin, 530 mM ATP, was mixed with 30 ml cell
xtract in a luminometer cuvette. Samples were mea-
ured in a Turner 2000 luminometer with a 5-s delay and
15-s integration period, and the resulting readings
ere expressed as arbitrary light units.
NA isolation and primer extension
BEF cells were transfected as described in the legend
o Fig. 1C and RNA was isolated from six identically
ransfected 10-cm plates 48 h after transfection. Total
NA was isolated by the method of Chomczynski and
acchi (1987), except samples were resuspended in 100
ml TE, pH 8.0, with no SDS added. The concentration of
the RNA was measured using a spectrophotometer at an
absorbance of 260 nm. Primer extension analysis was
performed as described in Current Protocols in Molecu-
lar Biology (Ausubel et al., 1987). Briefly, the oligo CAT-PE
(59 GCC ATT GGG ATA TAT CAA CGG TGG-39) was
labeled using standard kinase reaction conditions. The
oligo was then annealed to 15 mg of in vivo isolated RNA.
RNA and primers were incubated at 75°C for 2 min and
incubated at 55°C for 1 h in a 10-ml volume of 10 mM
Tris–Cl, pH 7.8, 1 mM EDTA, 1.25 M KCl. Annealing
reactions were then mixed with 40 ml extension mix (62.5
mM Tris–Cl, pH 8.3, 12.5 mM DTT, 1.25 mM MnCl , 1252
mg/ml actinomycin D, 0.33 mM dNTPs) and 1.0 ml (10 U)
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441BPV E1 MODULATES E2 ENHANCER FUNCTIONmurine leukemia virus reverse transcriptase (Promega),
incubated at 37°C for 45 min and stopped with 300 ml
100% ethanol. DNA was precipitated, washed, and re-
suspended in formamide loading dye. Samples were
denatured by boiling before they were separated by
electrophoresis in parallel with a DNA sequence ladder
and visualized by autoradiography.
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